Samsung Biologics Co., Ltd. (207940)

Profile

https://samsungbiologics.com

Samsung Biologics Co., Ltd. is a leading global contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals. Headquartered in Incheon, South Korea, the company provides end-to-end services from cell line development and process development to large-scale commercial manufacturing and aseptic fill-finish. Its core offerings include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and mRNA vaccines, supported by comprehensive quality assurance, biosafety testing, and analytical services. Samsung Biologics operates advanced facilities with substantial production capacity, serving clients in biopharma across South Korea, Europe, the United States, and other international markets. The company also engages in research and commercialization of biosimilar drugs, enabling pharmaceutical partners to accelerate development timelines and achieve efficient scaling. As a key player in the biologics sector, Samsung Biologics plays a vital role in the global supply chain for innovative therapies, delivering precision manufacturing and operational flexibility to meet diverse client needs in the rapidly evolving biopharmaceutical industry.